News Releases

Date	Title	Additional Formats
July 30, 2026	Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
July 20, 2026	Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
June 23, 2026	Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
May 22, 2026	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
May 20, 2026	Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
May 1, 2026	Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
April 30, 2026	Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
April 20, 2026	Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
April 6, 2026	Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
February 26, 2026	Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance (Corrected)